Literature DB >> 33289504

A Neurosurgeon's Guide to Cognitive Dysfunction in Adult Glioma.

Ramin A Morshed1, Jacob S Young1, Arlena A Kroliczek1, Mitchel S Berger1, David Brang2, Shawn L Hervey-Jumper1.   

Abstract

Cognitive decline is common among patients with low- and high-grade glioma and can significantly impact quality of life. Although cognitive outcomes have been studied after therapeutic interventions such as surgery and radiation, it is important to understand the impact of the disease process itself prior to any interventions. Neurocognitive domains of interest in this disease context include intellectual function and premorbid ability, executive function, learning and memory, attention, language function, processing speed, visuospatial function, motor function, and emotional function. Here, we review oncologic factors associated with more neurocognitive impairment, key neurocognitive tasks relevant to glioma patient assessment, as well as the relevance of the human neural connectome in understanding cognitive dysfunction in glioma patients. A contextual understanding of glioma-functional network disruption and its impact on cognition is critical in the surgical management of eloquent area tumors.
Copyright © 2020 by the Congress of Neurological Surgeons.

Entities:  

Keywords:  Cognition; Functional mapping; Glioma; Malignant glioma

Year:  2021        PMID: 33289504     DOI: 10.1093/neuros/nyaa400

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  1 in total

1.  Association of Neurological Impairment on the Relative Benefit of Maximal Extent of Resection in Chemoradiation-Treated Newly Diagnosed Isocitrate Dehydrogenase Wild-Type Glioblastoma.

Authors:  Alexander A Aabedi; Jacob S Young; Yalan Zhang; Simon Ammanuel; Ramin A Morshed; Cecilia Dalle Ore; Desmond Brown; Joanna J Phillips; Nancy Ann Oberheim Bush; Jennie W Taylor; Nicholas Butowski; Jennifer Clarke; Susan M Chang; Manish Aghi; Annette M Molinaro; Mitchel S Berger; Shawn L Hervey-Jumper
Journal:  Neurosurgery       Date:  2022-01-01       Impact factor: 5.315

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.